← All trials
NCT04973657
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 22, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Sep 30, 2022
- First posted
- Jul 22, 2021
- Last posted
- Nov 10, 2021
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Viking Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.